secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001619856-23-000070
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q1 net loss $28M, cash $291M; CB-010 dose expansion enrolling, CB-011 dosing initiated
--------------------------------------------------------------------------------

- Net loss of $28.0M in Q1 2023, vs $19.1M in Q1 2022, driven by higher R&D expenses.
- Cash and equivalents $291.0M as of March 31, 2023; cash runway into 2025.
- R&D expenses rose to $25.7M (Q1 2023) from $13.9M (Q1 2022) to advance pipeline.
- CB-010 ANTLER trial enrolling second-line LBCL in dose expansion; plan to report data H2 2023.
- CB-011 CaMMouflage Phase 1 dosing at dose level 1 for r/r multiple myeloma; IND for CB-012 planned H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/0001619856-23-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/crbu-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer